COMMUNIQUÉS West-GlobeNewswire
 
      -   
  MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million12/03/2018
-   
  Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast12/03/2018
-   
  Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast12/03/2018
-   
  Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results12/03/2018
-   
  Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update12/03/2018
-   
  Krystal Biotech Reports 2017 Financial Results and Business Progress12/03/2018
-   
  Celsion Corporation to Present at Upcoming Investor Conferences12/03/2018
-   
  Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights12/03/2018
-   
  Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 201812/03/2018
-   
  Mersana Appoints David A. Spellman as Chief Financial Officer12/03/2018
-   
  Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares12/03/2018
-   
  Delcath to Present at 30th Annual Roth Conference12/03/2018
-   
  Rockwell Medical Schedules Year End 2017 Earnings Call12/03/2018
-   
  Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura12/03/2018
-   
  Extendicare Announces Appointment of Michael Guerriere to Board of Directors12/03/2018
-   
  India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)12/03/2018
-   
  Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive12/03/2018
-   
  Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma12/03/2018
-   
  Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference12/03/2018
Pages